Article: Nicotinamide Riboside Supplementation Combined with Metabolic Activators Improves Cognitive Function in Alzheimer’s Disease: Clinical Findings

Alzheimer's Disease Clinical Neurological Health

Nicotinamide Riboside Supplementation Combined with Metabolic Activators Improves Cognitive Function in Alzheimer’s Disease: Clinical Findings

Objectives

To investigate whether supplementation of combined metabolic activators (CMA) consisting of L-carnitine tartrate, nicotinamide riboside (NR), serine, and N-acetyl-L-cysteine (NAC), could affect the global metabolism and brain function of Alzheimer's disease (AD) patients and be used for treatment of the disease.

Journal

Translational Neurodegeneration

Key Outcomes

CMA supplementation improved cognitive function by 29% in AD patients. Patients with high ADAS-Cog scores (worsened cognitive function) showed improvement with CMA supplementation.
CMA also improved serum markers related to AD, as well as markers of liver and kidney health in AD patients, as seen through significant decreases in levels of alanine aminotransferase (ALT) and uric acid.

Duration

8 weeks

Dose

2000 mg*
*One dose of 1 g NR, 12.35 g L-serine, 2.55 g N-acetyl-L-cysteine, and 3.73 g L-carnitine tartrate for the first 28 days and two doses for the next 56 days.

Study Design

Randomized, double-blind, placebo-controlled, phase II study in 69 Alzheimer's disease (AD) patients

See Published Study

Clinical

Nicotinamide Riboside Supplementation Increases Muscle Mitochondrial Biogenesis & Gut Health: Clinical Findings

Objectives To investigate the effects of long-term NR supplementation on mitochondrial biogenesis and metabolic health in humans. Journal Science Advances Key Outcomes In the BMI-discordant twi...